Skip to main content
. 2024 Mar 6;12(3):593. doi: 10.3390/biomedicines12030593

Table 5.

Summary of studies where prostate cancer patients with somatic BRCA mutated (sBRCA) cancers were treated with PARP inhibitors.

Clinical Trial Phase Treatment sBRCA gBRCA Results
PROFOUND trial [86] 3 Olaparib n = 51 n = 61 Radiographic PFS benefit was investigated. Risk of disease progression was similar for patients with:
  • -

    gBRCA: HR: 0.08 (95% CI: 0.03–0.18)

  • -

    sBRCA: HR: 0.16 (95% CI: 0.07–0.37)
TRITON 2 study [85] 3 rucaparib + + ORR was similar between patients with a gBRCA and sBRCA alterations
TRITON 3 study [89] 3 rucaparib + + Median PFS in the BRCA subgroup was 11.2 months for rucaparib vs. 6.4 month

gBRCA: germline BRCA mutation; ORR: objective response rate; PFS: progression-free survival.